Emily Chan

3.3k total citations
54 papers, 723 citations indexed

About

Emily Chan is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Molecular Biology. According to data from OpenAlex, Emily Chan has authored 54 papers receiving a total of 723 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Pulmonary and Respiratory Medicine, 22 papers in Surgery and 15 papers in Molecular Biology. Recurrent topics in Emily Chan's work include Bladder and Urothelial Cancer Treatments (18 papers), Urinary and Genital Oncology Studies (17 papers) and Renal cell carcinoma treatment (12 papers). Emily Chan is often cited by papers focused on Bladder and Urothelial Cancer Treatments (18 papers), Urinary and Genital Oncology Studies (17 papers) and Renal cell carcinoma treatment (12 papers). Emily Chan collaborates with scholars based in United States, Canada and Australia. Emily Chan's co-authors include Bradley A. Stohr, Karuna Garg, Julie Mak, Charles Zaloudek, Joseph T. Rabban, Hubert Lau, Alice C. Fan, Mark Merchant, Christian A. Kunder and Xiangnan Du and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and JNCI Journal of the National Cancer Institute.

In The Last Decade

Emily Chan

43 papers receiving 716 citations

Peers

Emily Chan
Marco Losa Switzerland
Elena Geuna Italy
Zhen Zheng China
Cyrus Amir United States
Yang‐Gun Suh South Korea
Daniel E. Soto United States
Zizhen Feng China
Frédérique Berger France
A. Fernandes United States
Tamara Aleksic United Kingdom
Marco Losa Switzerland
Emily Chan
Citations per year, relative to Emily Chan Emily Chan (= 1×) peers Marco Losa

Countries citing papers authored by Emily Chan

Since Specialization
Citations

This map shows the geographic impact of Emily Chan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emily Chan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emily Chan more than expected).

Fields of papers citing papers by Emily Chan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emily Chan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emily Chan. The network helps show where Emily Chan may publish in the future.

Co-authorship network of co-authors of Emily Chan

This figure shows the co-authorship network connecting the top 25 collaborators of Emily Chan. A scholar is included among the top collaborators of Emily Chan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emily Chan. Emily Chan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chan, Emily, Bradley A. Stohr, Ankur R. Sangoi, & Deepika Sirohi. (2025). Invasive urothelial carcinoma with chordoid and myxoid features shows increased RAS/RAF pathway alterations. Human Pathology. 163. 105882–105882. 1 indexed citations
2.
Papanicolau‐Sengos, Antonios, Kyung Park, Matija Snuderl, et al.. (2025). DNA Methylation-Based Classification of Kidney Neoplasms. Modern Pathology. 38(11). 100884–100884.
3.
Tretiakova, Maria, Carlos J. Suarez, Sean R. Williamson, et al.. (2025). Urothelial carcinoma with osteoclast-like giant cells: An expanded immunohistochemical and molecular profile. American Journal of Clinical Pathology. 164(2). 257–264. 2 indexed citations
4.
Friedman, Lisa S., et al.. (2025). MAPK1IP1L::TFE3-rearranged renal cell carcinoma: a novel fusion adding to the differential diagnosis of oncocytic renal neoplasms. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 487(4). 915–920. 1 indexed citations
5.
Stohr, Bradley A., et al.. (2024). Clinicopathologic and Molecular Characterization of High-Risk Human Papillomavirus–Positive Carcinomas of the Urinary Tract. Archives of Pathology & Laboratory Medicine. 149(1). 30–38.
6.
Pinard, Amélie, et al.. (2024). Next-generation sequencing has diagnostic utility in challenging small/flat urothelial lesions. Annals of Diagnostic Pathology. 73. 152370–152370. 1 indexed citations
7.
Bobba, Kondapa Naidu, Anil P. Bidkar, Niranjan Meher, et al.. (2024). Development of CD46 targeted alpha theranostics in prostate cancer using 134Ce/225Ac-Macropa-PEG4-YS5. Theranostics. 14(4). 1344–1360. 13 indexed citations
8.
Greenland, Nancy, Matthew R. Cooperberg, Peter R. Carroll, et al.. (2024). Morphologic patterns observed in prostate biopsy cases with discrepant grade group and molecular risk classification. The Prostate. 84(11). 1076–1085.
9.
Greenland, Nancy, Janet E. Cowan, Bradley A. Stohr, et al.. (2023). Large cribriform glands (> 0.25 mm diameter) as a predictor of adverse pathology in men with Grade Group 2 prostate cancer. Histopathology. 84(4). 614–623. 5 indexed citations
10.
Ziffle, Jessica Van, et al.. (2023). Epithelioid Angiomyolipoma With Prominent Papillary Architecture Mimicking Renal Cell Carcinoma: A Case Report. International Journal of Surgical Pathology. 32(1). 206–208.
11.
Klauser, Paul C., Li Cao, Kondapa Naidu Bobba, et al.. (2023). Covalent Proteins as Targeted Radionuclide Therapies Enhance Antitumor Effects. ACS Central Science. 9(6). 1241–1251. 30 indexed citations
12.
Gupta, Rohit, Ajay Ravindranathan, Emily Chan, et al.. (2023). Somatic mosaic SOX10 indel mutations underlie a form of segmental schwannomatosis. Acta Neuropathologica. 146(6). 857–860. 5 indexed citations
13.
Chou, Jonathan, Martin Sjöström, Emily A. Egusa, et al.. (2022). TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells. European Urology Oncology. 5(6). 714–718. 56 indexed citations
14.
15.
Sangoi, Ankur R., Emily Chan, Eman Abdulfatah, et al.. (2022). p53 null phenotype is a “positive result” in urothelial carcinoma in situ. Modern Pathology. 35(9). 1287–1292. 5 indexed citations
16.
Greenland, Nancy, Matthew R. Cooperberg, Anthony Wong, et al.. (2021). Molecular risk classifier score and biochemical recurrence risk are associated with cribriform pattern type in Gleason 3+4=7 prostate cancer. Investigative and Clinical Urology. 63(1). 27–27. 10 indexed citations
17.
18.
Sangoi, Ankur R., Emily Chan, Bradley A. Stohr, & Lakshmi P. Kunju. (2020). Invasive plasmacytoid urothelial carcinoma: A comparative study of E-cadherin and P120 catenin. Human Pathology. 102. 54–59. 12 indexed citations
19.
Gonsalves, Wilson I., Michelle R. Mahoney, Daniel J. Sargent, et al.. (2014). Patient and Tumor Characteristics and BRAF and KRAS Mutations in Colon Cancer, NCCTG/Alliance N0147. JNCI Journal of the National Cancer Institute. 106(7). 127 indexed citations
20.
Du, Xiangnan, Emily Chan, Mark Merchant, et al.. (2012). FGFR3 Stimulates Stearoyl CoA Desaturase 1 Activity to Promote Bladder Tumor Growth. Cancer Research. 72(22). 5843–5855. 72 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marco Losa Breakdown of academic impact, for papers by Elena Geuna Breakdown of academic impact, for papers by Zhen Zheng Breakdown of academic impact, for papers by Cyrus Amir Breakdown of academic impact, for papers by Yang‐Gun Suh Breakdown of academic impact, for papers by Daniel E. Soto Breakdown of academic impact, for papers by Zizhen Feng Breakdown of academic impact, for papers by Frédérique Berger Breakdown of academic impact, for papers by A. Fernandes Breakdown of academic impact, for papers by Tamara Aleksic
Rankless by CCL
2026